During the study, participants completed a survey every evening pertaining to migraine occurrence and possible migraine predictors on an iPhone specific application.
INP104 uses proprietary technology to deliver a lower dose (1.45mg) of dihydroergotamine mesylate (DHE) to the upper nasal space.
While it does not influence migraine severity, the renin-angiotensin system (RAS) has an important role in the pathophysiology of migraine.
Occipital nerve stimulation has been proposed to treat refractory chronic cluster headache but this study aimed to evaluate ONS long-term efficacy in rCCH.
The HER-MES study included 777 adult patients suffering from at least 4 migraine days/month and who were naïve to, not suitable for, or had previously failed up to 3 prophylactic treatments.
This phase 3, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of IV infusion of eptinezumab to prevent migraine in adults with chronic migraine.
This post hoc analysis assessed the effect of onabotulinumtoxinA on clinically meaningful changes in headache severity, headache-related impact, and QOL in adults with chronic migraine.
Women with migraine are more likely to avoid pregnancy, especially if they have chronic or menstrual migraine and are relatively younger.
Previously, the device had only been approved in those with episodic migraine.
Qtrypta delivers zolmitriptan, a selective 5-HT1B/1D receptor agonist, using the Company’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology that consists of a drug-coated microneedle patch.